Rituximab as a therapeutic tool in severe mixed cryoglobulinemia.

@article{Roccatello2008RituximabAA,
  title={Rituximab as a therapeutic tool in severe mixed cryoglobulinemia.},
  author={Dario Roccatello and Simone Baldovino and Daniela Rossi and Osvaldo Giachino and Morteza Mansouri and Carla Naretto and Debora Di Simone and Simona Francica and Roberto Cavallo and Mirella Alpa and Franca Napoli and Luigi Massimino Sena},
  journal={Clinical reviews in allergy & immunology},
  year={2008},
  volume={34 1},
  pages={
          111-7
        }
}
Type II mixed cryoglobulinemia (MC) is a systemic vasculitis, associated in most cases with hepatitis C virus (HCV) infection, sustained by proliferation of oligoclonal cells. Systemic B cell depletion and clinical remission can be achieved in non-Hodgkin lymphoma by human/mouse chimeric monoclonal antibody that specifically reacts with the CD20 antigen (rituximab). Similar effects could be expected in type II MC. Twelve patients, mean age 61.9 years (range 37-76), 11 with HCV infection… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 34 CITATIONS

Similar Papers

Loading similar papers…